Neoleukin Therapeutics announced publication of de novo protein decoys that block COVID-19 infection
On Nov. 5, 2020, Neoleukin Therapeutics announced the publication in Science of research describing novel molecules designed to…
Immunic announced 200 patients enrolled in phase 2 CALVID-1 trial of IMU-838 for treatment of COVID-19
On Nov. 2, 2020, Immunic announced that the company had enrolled and randomized 200 patients, pre-specified in the…
InBios awarded $12.7M to boost production of two COVID-19 diagnostics
On Oct. 31, 2020, the U.S. Department of Health and Human Services and the U.S. Department of Defense…
Trials of University of Oxford’s Coronavirus vaccine began in Kenya
On Oct. 30, 2020, the University of Oxford announced that Kenya had joined the global efforts in search…
Icosavax launched COVID-19 vaccine program with preclinical data and $165 million in new funding
On Oct. 30, 2020, Icosavax announced the launch of the companyï¾’s COVID-19 vaccine program with preclinical data on…
HHS and DOD announced $12.7 million contract with InBios to boost US production of rapid COVID-19 tests
On Oct. 30, 2020, the U.S. Department of Health and Human Services (HHS) and the U.S. Department of…
Oxford University began COVID-19 test for individuals without symptoms
On Oct. 29, 2020, the University of Oxford announced a new pilot scheme to assess the use of…
PerkinElmer COVID-19 test kit receives FDA Emergency Use Authorization for sample pooling
On Oct. 29, 2020, PerkinElmer announced that the FDA had issued Emergency Use Authorization (EUA) to allow sample…
Emulate collaborated with FDA to apply lung-chip to evaluate safety of COVID-19 vaccines
On Oct. 29, 2020, Emulate announced that it had entered into a Cooperative Research and Development Agreement (CRADA)…
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Life Science News | Non-Profit Research
UC Berkeley launched pop-up lab to monitor Bay Area sewage for COVID-19
On Oct. 29, 2020, UC Berkeley announced that it had launched a new high-throughput pop-up lab – a…
NIH scientists discovered key pathway in lysosomes that coronaviruses use to exit cells
On Oct. 28, 2020, researchers at the NIH announced that they had discovered a biological pathway that the…
Additional COVID-19 related genes ï¾– both helpful and harmful ï¾– revealed in massive screen
On Oct. 27, 2020, researchers at Yale University and the Broad Institute of MIT and Harvard screened hundred…
Antibodies co-invented by Scripps Research and IAVI developed as a potential COVID-19 therapy
On Aug. 27, 2020, immunologists at Scripps Research, in partnership with colleagues at the IAVI Neutralizing Antibody Center,…
PerkinElmer received CE Mark for multi-analyte respiratory panel including COVID-19
On Oct. 26, 2020, PerkinElmer announced that its PKampï¾™ Respiratory SARS-CoV-2 RT-PCR Panel had received clearance to be…
Taconic Biosciences launched critical model for COVID-19 research
On Oct. 26, 2020, Taconic Biosciences announced immediate humanized ACE2 mouse model availability for COVID-19 research. The SARS-CoV-2…
Membrion molecular coating to prevent COVID-19 virus from passing through cloth face masks
On Oct. 26, 2020, Membrion announced a breakthrough in the fight against the COVID-19 virus: a molecular coating…
Entos Pharma awarded $5 million in NRC IRAP funding to conduct phase I Clinical trial of COVID-19 DNA vaccine
On Oct. 23, 2020, Entos Pharmaceuticals announced it was receiving advisory services and funding of up to $5…
Global clinical trials of COVID-19 vaccine resumed
On Oct. 23, 2020, the U.S. FDA authorised a restart of clinical trials of the ChAdOx1 nCov-2019 Oxford…
FDA authorised restart of the COVID-19 AZD1222 vaccine US phase III trial
On Oct. 23, 2020, AstraZeneca announced that the clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, had…
FDA approved Gilead’s antiviral Veklury (remdesivir) for treatment of COVID-19
On Oct. 22, 2020, Gilead Sciences announced that the FDA had approved the antiviral drug Veklury (remdesivir) for…
ImmunityBio, NantKwest announced first patient dosed in phase 1 clinical trial of second-generation COVID-19 vaccine candidate
On Oct. 21, 2020, ImmunityBio and NantKwest announced that the first patient had been dosed in the Phase…
European Investment Bank provided Immunic with ï¾€245 million to support development of COVID-19 therapy
On Oct. 20, 2020, the European Investment Bank (EIB) and Immunic announced the signing of a ï¾€24.5 million…
Evidence review confirmed CDC guidance about infectivity of novel coronavirus
On Oct. 20, 2020, researchers at Oregon Health & Science University (OHSU) and Oregon State University (OSU) reported…
Mateon’s phase 2 global study for OT-101/ TGF- Inhibitor against COVID-19 cleared for patient enrollment in Argentina
On Oct. 19, 2020, Mateon Therapeutics announced the receipt of approval from Republica Argentina Poder Ejecutivo Nacional, the…
LabCorp launched quantitative antibody test to assess effectiveness ef COVID-19 vaccines in clinical trials
On Oct. 19, 2020, LabCorp announced a test that provided a quantitative measurement of an individualï¾’s SARS-CoV-2 IgG…
Public health experts at DSHS and UTHealth collaborated on large COVID-19 serological testing assessment
On Oct. 19, 2020, the University of Texas Health Science Center at Houston (UTHealth) announced a partnership with…
University of Oxford scientists developed extremely rapid diagnostic test for Covid-19
On Oct. 15, 2020, scientists from the University of Oxford ï¾’s Department of Physics announced they had developed…
FDA authorized phase 1 trial of ImmunityBioï¾’s novel COVID-19 vaccine candidate hAd5 to drive T cell and antibody immunity
On Oct. 15, 2020, ImmunityBio announced it had received authorization from the FDA to begin a Phase I…
Tonix Pharmaceuticals enrolled first participant in PRECISION Study for COVID-19 vaccines and therapeutics
On Oct. 15, 2020, Tonix Pharmaceuticals announced that the first participant was enrolled in the observational PRECISION study…
FDA approved first treatment for Ebola virus
On Oct. 14, 2020, the FDA approved Regeneron Pharmaceutical’s Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three…